Market Overview

ACADIA Initiates Phase II Trial with Pimavanserin for Alzheimer's Disease Psychosis

ACADIA Pharmaceuticals (NASDAQ: ACAD) today
announced that it has initiated a Phase II feasibility trial designed to
examine the efficacy and safety of pimavanserin as a treatment for
patients with Alzheimer's disease psychosis (ADP). No drug is approved
in the United States to treat ADP and the off-label use of current
antipsychotics is linked to increased mortality, serious adverse events,
and cognitive decline in elderly patients with dementia-related
psychosis.

“The development of psychosis and related behavioral disturbances in
patients with Alzheimer's disease carries a poor prognosis and often has

See full press release

Posted-In: News Guidance Offerings Contracts Management Global

 

Related Articles (ACAD)

Around the Web, We're Loving...

Partner Network

Get Benzinga's Newsletters